# The Safety and Dose Response to Single Anal Doses of NRL001

> **NCT06593743** · PHASE1 · COMPLETED · sponsor: **Norgine** · enrollment: 44 (actual)

## Conditions studied

- Faecal Incontinence

## Interventions

- **DRUG:** Perianal NRL001 Gel 3 strengths
- **DRUG:** Intraanal NRL001 Gel 2 strengths
- **DRUG:** Intrarectal NRL001 Gel
- **DRUG:** NRL001: 10mg suppository

## Key facts

- **NCT ID:** NCT06593743
- **Lead sponsor:** Norgine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-07
- **Final completion:** 2013-11-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593743, "The Safety and Dose Response to Single Anal Doses of NRL001". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06593743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*